
The Canadian authorization covers adults with symptomatic class II-III disease and follows positive results from a Phase 3 trial.
Cytokinetics said Health Canada has authorized MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), New York Heart Association class II-III. The company said the Canadian decision is the drug’s fifth regulatory approval in less than a year.
The authorization was supported by results from the Phase 3 SEQUOIA-HCM trial. After 24 weeks, patients taking MYQORZO had a greater improvement in exercise capacity than those taking placebo, according to the trial results.
The Canadian product monograph includes a boxed warning about heart failure risk. It calls for echocardiogram checks before and during treatment, and says starting MYQORZO in patients with a left ventricular ejection fraction below 55% is not recommended.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.